Abstract
Background: The Observational Health Data Sciences and Informatics (OHDSI) network enables access to billions of deidentified, standardized health records and built-in analytics software for observational health research, with numerous potential applications to dermatology. While the use of the OHDSI has increased steadily over the past several years, review of the literature reveals few studies utilizing OHDSI in dermatology. To our knowledge, the University of Colorado School of Medicine is unique in its use of OHDSI for dermatology big data research. Summary: A PubMed search was conducted in August 2020, followed by a literature review, with 24 of the 72 screened articles selected for inclusion. In this review, we discuss the ways OHDSI has been used to compile and analyze data, improve prediction and estimation capabilities, and inform treatment guidelines across specialties. We also discuss the potential for OHDSI in dermatology – specifically, ways that it could reveal adherence to available guidelines, establish standardized protocols, and ensure health equity. Key Messages: OHDSI has demonstrated broad utility in medicine. Adoption of OHDSI by the field of dermatology would facilitate big data research, allow for examination of current prescribing and treatment patterns without clear best practice guidelines, improve the dermatologic knowledge base and, by extension, improve patient outcomes.
References
1.
“
Welcome to OMOP – OHDSI.
” https://ohdsi.org/omop/ (accessed Nov. 12, 2020).2.
Hripcsak
G
, Duke
JD
, Shah
NH
, Reich
CG
, Huser
V
, Schuemie
MJ
, et al. Observational Health Data Sciences and Informatics (OHDSI): Opportunities for Observational Researchers
. Stud Health Technol Inform
. 2015
;216
:574
–8
.
[PubMed]
1879-83653.
Frieden
TR
. “Evidence for Health Decision Making — Beyond Randomized, Controlled Trials
,” , Aug.
02
, 2017
. https://www.nejm.org/doi/10.1056/NEJMra1614394 (accessed Oct. 31, 2020). 4.
Bothwell
LE
, Greene
JA
, Podolsky
SH
, Jones
DS
. “Assessing the Gold Standard — Lessons from the History of RCTs
,” , Jun.
01
, 2016
. https://www.nejm.org/doi/10.1056/NEJMms1604593 (accessed Oct. 31, 2020). 5.
Concato
J
, Shah
N
, Horwitz
RI
. Randomized, controlled trials, observational studies, and the hierarchy of research designs
. N Engl J Med
. 2000
Jun
;342
(25
):1887
–92
.
[PubMed]
0028-47936.
Schuemie
MJ
, Ryan
PB
, Hripcsak
G
, Madigan
D
, Suchard
MA
. Improving reproducibility by using high-throughput observational studies with empirical calibration
. Philos Trans- Royal Soc, Math Phys Eng Sci
. 2018
Sep
;376
(2128
):20170356
.
[PubMed]
1364-503X7.
Sen
A
, Chakrabarti
S
, Goldstein
A
, Wang
S
, Ryan
PB
, Weng
C
. GIST 2.0: A scalable multi-trait metric for quantifying population representativeness of individual clinical studies
. J Biomed Inform
. 2016
Oct
;63
:325
–36
.
[PubMed]
1532-04648.
Bartlett
VL
, Dhruva
SS
, Shah
ND
, Ryan
P
, Ross
JS
. Feasibility of Using Real-World Data to Replicate Clinical Trial Evidence
. JAMA Netw Open
. 2019
Oct
;2
(10
):e1912869
.
[PubMed]
2574-38059.
Tong
J
, Duan
R
, Li
R
, Scheuemie
MJ
, Moore
JH
, Chen
Y
. Robust-ODAL: learning from heterogeneous health systems without sharing patient-level data
. Pac Symp Biocomput
. 2020
;25
:695
–706
.
[PubMed]
2335-693610.
Gini
R
, Schuemie
M
, Brown
J
, Ryan
P
, Vacchi
E
, Coppola
M
, et al. Data Extraction and Management in Networks of Observational Health Care Databases for Scientific Research: A Comparison of EU-ADR, OMOP, Mini-Sentinel and MATRICE Strategies
. EGEMS (Wash DC)
. 2016
Feb
;4
(1
):1189
.
[PubMed]
2327-921411.
Yu
Y
, Ruddy
KJ
, Hong
N
, Tsuji
S
, Wen
A
, Shah
ND
, et al. ADEpedia-on-OHDSI: A next generation pharmacovigilance signal detection platform using the OHDSI common data model
. J Biomed Inform
. 2019
Mar
;91
:103119
.
[PubMed]
1532-046412.
Yu
Y
, Ruddy
KJ
, Wen
A
, Zong
N
, Tsuji
S
, Chen
J
, et al. Integrating Electronic Health Record Data into the ADEpedia-on-OHDSI Platform for Improved Signal Detection: A Case Study of Immune-related Adverse Events
. AMIA Jt Summits Transl Sci Proc
. 2020
May
;2020
:710
–9
.
[PubMed]
2153-406313.
Li
Y
, Ryan
PB
, Wei
Y
, Friedman
C
. A Method to Combine Signals from Spontaneous Reporting Systems and Observational Healthcare Data to Detect Adverse Drug Reactions
. Drug Saf
. 2015
Oct
;38
(10
):895
–908
.
[PubMed]
0114-591614.
Chandler
RE
. Nintedanib and ischemic colitis: signal assessment with the integrated use of two types of real-world evidence, spontaneous reports of suspected adverse drug reactions, and observational data from large health-care databases
. Pharmacoepidemiol Drug Saf
. 2020
Aug
;29
(8
):951
–7
.
[PubMed]
1053-856915.
Jiang
G
, Yu
Y
, Kingsbury
PR
, Shah
N
. Augmenting Medical Device Evaluation Using a Reusable Unique Device Identifier Interoperability Solution Based on the OHDSI Common Data Model
. Stud Health Technol Inform
. 2019
Aug
;264
:1502
–3
.
[PubMed]
1879-836516.
Duke
JD
, Ryan
PB
, Suchard
MA
, Hripcsak
G
, Jin
P
, Reich
C
, et al. Risk of angioedema associated with levetiracetam compared with phenytoin: findings of the observational health data sciences and informatics research network
. Epilepsia
. 2017
Aug
;58
(8
):e101
–6
.
[PubMed]
0013-958017.
Hripcsak
G
, Ryan
PB
, Duke
JD
, Shah
NH
, Park
RW
, Huser
V
, et al. Characterizing treatment pathways at scale using the OHDSI network
. Proc Natl Acad Sci USA
. 2016
Jul
;113
(27
):7329
–36
.
[PubMed]
0027-842418.
Zhang
X
, Wang
L
, Miao
S
, Xu
H
, Yin
Y
, Zhu
Y
, et al. Analysis of treatment pathways for three chronic diseases using OMOP CDM
. J Med Syst
. 2018
Nov
;42
(12
):260
.
[PubMed]
0148-559819.
Polubriaginof
FC
, Vanguri
R
, Quinnies
K
, Belbin
GM
, Yahi
A
, Salmasian
H
, et al. Disease Heritability Inferred from Familial Relationships Reported in Medical Records
. Cell
. 2018
Jun
;173
(7
):1692
–1704.e11
.
[PubMed]
0092-867420.
Wang
Q
, Reps
JM
, Kostka
KF
, Ryan
PB
, Zou
Y
, Voss
EA
, et al. Development and validation of a prognostic model predicting symptomatic hemorrhagic transformation in acute ischemic stroke at scale in the OHDSI network
. PLoS One
. 2020
Jan
;15
(1
):e0226718
.
[PubMed]
1932-620321.
Choi
YI
, Kim
YJ
, Chung
JW
, Kim
KO
, Kim
H
, Park
RW
, et al. Effect of Age on the Initiation of Biologic Agent Therapy in Patients With Inflammatory Bowel Disease: Korean Common Data Model Cohort Study
. JMIR Med Inform
. 2020
Apr
;8
(4
):e15124
–15124
.
[PubMed]
2291-969422.
Meystre
SM
, Heider
PM
, Kim
Y
, Aruch
DB
, Britten
CD
. Automatic trial eligibility surveillance based on unstructured clinical data
. Int J Med Inform
. 2019
Sep
;129
:13
–9
.
[PubMed]
1386-505623.
Maier
C
, Lang
L
, Storf
H
, Vormstein
P
, Bieber
R
, Bernarding
J
, et al. Towards Implementation of OMOP in a German University Hospital Consortium
. Appl Clin Inform
. 2018
Jan
;9
(1
):54
–61
.
[PubMed]
1869-032724.
Yoon
D
, Ahn
EK
, Park
MY
, Cho
SY
, Ryan
P
, Schuemie
MJ
, et al. Conversion and Data Quality Assessment of Electronic Health Record Data at a Korean Tertiary Teaching Hospital to a Common Data Model for Distributed Network Research
. Healthc Inform Res
. 2016
Jan
;22
(1
):54
–8
.
[PubMed]
2093-368125.
S. C.
You
, et al., “Conversion of National Health Insurance Service-National Sample Cohort (NHIS-NSC) Database into Observational Medical Outcomes Partnership- Common Data Model (OMOP-CDM)
,” p. 4.26.
Lima
DM
, Rodrigues-Jr
JF
, Traina
AJ
, Pires
FA
, Gutierrez
MA
. “Transforming Two Decades of ePR Data to OMOP CDM for Clinical Research
,” p. 5. F. A. Alnofal, A. A. Alrwisan, and T. M. Alshammari, “Real-world data in Saudi Arabia: Current situation and challenges for regulatory decision-making. - Abstract - Europe PMC.” https://europepmc.org/article/med/32458499 (accessed Oct. 31, 2020).27.
Alnofal FA, Alrwisan AA, Alshammari TM. Real-world data in Saudi Arabia: current situation and challenges for regulatory decision-making. Pharmacoepidemiol Drug Saf. 2020 Oct;29(10):1303–6.
28.
Boyce
RD
, Handler
SM
, Karp
JF
, Perera
S
, Reynolds
CF
3rd. Preparing Nursing Home Data from Multiple Sites for Clinical Research - A Case Study Using Observational Health Data Sciences and Informatics
. EGEMS (Wash DC)
. 2016
Oct
;4
(1
):1252
.
[PubMed]
2327-9214© 2021 S. Karger AG, Basel
2021
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
